期刊
NEUROLOGICAL SCIENCES
卷 44, 期 9, 页码 3123-3131出版社
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10072-023-06740-w
关键词
Parkinson's disease; Depression; Delphi Consensus; SSRI; Multimodal antidepressants
The diagnosis of depression in Parkinson's disease is challenging due to overlapping symptoms. A panel of Italian specialists reached a consensus that depression is a risk factor for Parkinson's disease, with neuropathological abnormalities playing a role. Multimodal and SSRI antidepressants are confirmed as effective options for treating depression in Parkinson's disease.
BackgroundDepression is a prodromic and a frequent non-motor symptom of Parkinson's disease, associated to reduced quality of life and poor outcomes. The diagnosis of depression in parkinsonian patients represents a challenge due to the overlapping of symptoms typical of the two conditions.MethodsA Delphi panel survey was performed to reach a consensus amongst different Italian specialists on four main topics: the neuropathological correlates of depression, main clinical aspects, diagnosis, and management of depression in Parkinson's disease.Results and conclusionExperts have recognized that depression is an established risk factor of PD and that its anatomic substrate is related to the neuropathological abnormalities typical of the disease. Multimodal and SSRI antidepressant have been confirmed as a valid therapeutic option in the treatment of depression in PD. Tolerability, safety profile, and potential efficacy on broad spectrum of symptoms of depression including cognitive symptoms and anhedonia should be considered when selecting an antidepressant and the choice should be tailored on the patients' characteristics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据